RESUMO
This study was conducted in order to compare well established used chemical anticoccidial medication (diclazuril) against natural prepared safe alternative products of garlic extract (GE), Moringa oleifera (MO) leaves extract, onion extract (OE), in order to control experimentally infected with Eimeria tenella species in chickens. Performance parameter in form of average body weight (ABW) and feed conversion rate (FCR) were studied together with biochemical parameters (malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT), mortality rate, oocyst count in addition to total white blood cell (WBCs), lymphocytes and heterophils counts. Histopathological examination of intestinal tract in all test groups was studied. Results revealed that the lowest mortality rate was found in group treated with MO leaves extract. All challenged herbal extract treated groups revealed ABW and FCR lower than diclazuril treated infected group. All treated groups were lower in both average lesion score and average oocyst count two weeks post challenge when compared with control positive group indicate positive impact of all studied therapies either chemical or herbal products but with variable degrees as best effect was diclazuril followed by MO group, followed by GE group and finally group treated with OE. Experimental infection of chickens with E. tenella oocysts significantly increased MDA concentration when compared with control negative non-treated group (P < 0.01). However, infected birds fed with OE, GE, MO leaves extracts and diclazuril administration for a week pre-infection had significantly declined MDA concentrations compared with infected non-treated (P < 0.01). Control positive birds showed significant decrease in SOD and CAT activities vs. the healthy birds either at week pre-infection or at two days' post-infection (P < 0.01). However, SOD activities in birds fed with OE, MO leaves extract and diclazuril for a week pre-infection significantly higher (P < 0.01) than control positive. Histopathological finding revealed that best was group treated with diclazuril followed by group received MO, followed by group received GE and finally group received OE. It could be concluded that herbal extract may be representing a good alternative anticoccidial medications specially that the later may developed resistance for many Eimeria species in continuous use in veterinary field.
RESUMO
BACKGROUND AND AIM: Campylobacteriosis is one of the most well-characterized bacterial foodborne infections worldwide that arise chiefly due to the consumption of foods of animal origin such as poultry, milk, and their products. The disease is caused by numerous species within the genus Campylobacter, but Campylobacter jejuni is the most commonly isolated species from established cases of human campylobacteriosis. This study was conducted to determine the prevalence and virulence of Campylobacter isolates from human, chicken, and milk and milk products in Egypt. MATERIALS AND METHODS: A total of 1299 samples (547 chicken intestine and liver, 647 milk and milk products, and 105 human stool) were collected and microbiologically investigated, confirmed by multiplex polymerase chain reaction (PCR) targeting the 23S rRNA, hipO, and glyA genes specific for Campylobacter spp., C. jejuni, and Campylobacter Coli, respectively, followed by virulence genes (Campylobacter adhesion to fibronectin F [cadF] and cdtB) detection using PCR. RESULTS: About 38.09%, 37.84%, and 8.5% of human stool, chicken, and milk and milk product samples, respectively, were bacteriologically positive, with a total of 302 Campylobacter isolates. All isolates were molecularly confirmed as Campylobacter spp. (100%) where 285 isolates (94.37%) were identified as C. jejuni and 17 isolates (5.62%) as C. coli. Regarding the virulence pattern, all isolates (100%) carried cadF gene while cytolethal distending toxin B gene was definite in 284/302 isolates (94%), concisely, 282/285 (98.94%) C. jejuni isolates, and in 2/17 (11.76%) C. coli isolates. CONCLUSION: The widespread presence of these highly virulent Campylobacter, especially C. jejuni, proofs the urgent need for the implementation of stringent control, public health, and food protection strategies to protect consumers from this zoonotic pathogen. The availability of information about pathogen virulence will enable enhanced local policy drafting by food safety and public health officials.
RESUMO
BACKGROUND: Poultry bacterial pathogens are mainly controlled by using high-cost sanitary measures and medical treatment. However, the drug-resistant strains of pathogens continuously emerge, and medical treatments are often ineffective. Moreover, there is increasing public objections to drug residues in poultry products. The other important type of control is the vaccination which depends on immunity. This immunological control is the major practical alternative to chemotherapy. Success of vaccines in combating poultry diseases depends mainly on the choice of the proper type of vaccines, correct time of its usage, and method of administration.The types of vaccines include attenuated live vaccines, and these vaccines were shown to be effective in inducing protection. The second type is killed vaccine or whole bacteria extracts which is less successful in providing protection compared to live vaccines. The metabolic product vaccine (toxoids) is the third type of vaccine. The recombinant DNA technique was adopted to produce the protective antigens in a sufficient amount and in cost-effective ways. CONCLUSIONS: Protection studies against bacterial diseases were performed by using several trials: living vaccines (live attenuated vaccines; live, non-pathogenic microorganisms; live, low virulence microorganism), inactivated (killed) vaccines (heat-inactivated, chemical inactivates, radiation), metabolic product vaccines (toxoids), subunit vaccines (whole cell proteins, outer membrane proteins, purified flagellar proteins (flagellin), fimbrial proteins, pilus proteins, lipopolysaccharides), vaccines produced by recombinant deoxyribonucleic acid (DNA) technology, and DNA vaccines.
